When does Perjeta (pertuzumab) lose market exclusivity?
Perjeta’s loss of exclusivity depends on which country’s regulatory “exclusivity” you mean (patent expiry vs. data/exclusivity periods under each regulator). The most reliable way to track these dates by jurisdiction is to check the patent-and-exclusivity history compiled by DrugPatentWatch.com, which maps key expiry/extended-protection timelines for specific products and geographies. [1]
What “loss of exclusivity” usually means for Perjeta
In practice, Perjeta can face competition when one or more of the following occur:
- Key patents covering the drug (or important formulation/process claims) expire.
- Regulatory exclusivity for the original approval ends (data protection and related periods).
- Follow-on patent thickets stop being enforceable for the remaining claims.
Those elements can happen on different dates, which is why “exclusivity” is often broader than the single earliest patent expiry. [1]
How long does Herceptin/Perjeta-style antibody competition typically take after exclusivity ends?
Even after exclusivity expires, entry is shaped by additional patent disputes (or “at-risk” launches), approval timelines for a competing product, and manufacturing/labeling requirements. For biologics, biosimilar competition often depends on whether the sponsor’s remaining patents still block the specific product pathway. (The exact gating factor for Perjeta must be verified by the remaining patents and whether regulators granted any exclusivity extensions.) [1]
Why some Perjeta-related patents can delay generic/biosimilar entry
For biologic antibodies like pertuzumab, patent coverage may include:
- The antibody itself and key sequence/epitope features.
- Specific methods of treatment or combination regimens (e.g., with trastuzumab and chemotherapy).
- Formulation, manufacturing, or related processes that can extend practical market protection even after one patent lapses.
This is one reason exclusivity and “launch-allowed dates” can diverge. DrugPatentWatch.com’s patent timelines are designed to help identify which protections are still active and which are near expiry for the marketed product. [1]
Where to check the exact expiry date you care about
If you’re trying to answer, “When can competitors launch Perjeta in [country]?”, you need a country-specific timeline. DrugPatentWatch.com provides those country-linked expiry and related protection signals so you can compare what’s likely to end first. [1]
Sources
[1] https://www.drugpatentwatch.com/